Image: Sebastian Ens

Sebastian Ens

Associate, Corporate Department
TaunusTurm - Taunustor 1
Frankfurt am Main, HE

Fax: 49 69 907485-320


Sebastian Ens is an associate in the Corporate practice of Paul Hastings and is based in the firm's Frankfurt office. He focuses on M&A, joint ventures and corporate restructurings as well as on corporate, commercial and contract law. He also advises on foreign direct investment reviews. Before joining Paul Hastings in 2018, Mr. Ens worked for a major British law firm in Frankfurt for several years. Mr. Ens is fluent in German, English, French and Portuguese.


  • Landgericht Freiburg, 2nd State Exam, 2008

  • Albert-Ludwigs-Universität Freiburg, 1st State Exam, 2006

  • Université Paris Descartes (Paris V), D.E.U.G. droit

Speaking Engagements

  • Kosten sparen durch Beurkundung in der Schweiz?, M&A Review 2014, S. 245-249 (together with Dr. T. Rosenboom).

  • Gläubigerschutz im deutschen und angloamerikanischen Recht - Bestandsaufnahme und Reformtendenzen, StudZR 2005, S. 81-130 (together with S. Micsunescu).


  •  German-Brazilian Lawyers Association (DBJV)

  • Wissenschaftliche Vereinigung für Unternehmens- und Gesellschaftsrecht (VGR) (an academic association for business and corporate law)

Recent Representations

(with Paul Hastings only)

  • Advised the Danish brewery group Carlsberg on the acquisition of Wernesgrüner Brauerei from Bitburger Braugruppe by Carlsberg Germany. Wernesgrüner is one of the most traditional German beer brands. The roots of the brewery can be traced back to the 15th century. The current brewery, which has been part of Bitburger Braugruppe since 2002, has an annual capacity of around 1 million hectoliters.

  • Advised Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), one of the leading Chinese healthcare groups, in forming a strategic alliance with Biopharmaceutical New Technologies of Germany ("BioNTech"; Nasdaq: BNTX) to develop and commercialize a vaccine that prevents COVID-19 infections using BioNTech's mRNA vaccine candidate BNT162.

  • Advised Hansol Paper Co., Ltd., the largest paper manufacturer in Korea, on the sale of its European Schades and R+S group companies to U.S-based Iconex, a market leader in low-cost paper receipt and differentiated label solutions.






Landgericht Freiburg, 2 St Exam 2008
Albert-Ludwigs-Universitat Freiburg, 1 St Exam 2006
Universite Paris Descartes, D.E.U.G. 2001

Get In Touch With Us

Contact Us